In conclusion, repeated intravenous administration of T22-PE24-H6 achieves a potent antineoplastic effect in a CXCR4+ AML mouse model by inducing a large reduction in leukemic cells in the BM and liver. The gene discussed is CXCR4; the disease is acute myeloid leukemia.